Company news

Vistagen Therapeutics, Inc. news in 2026

Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update

November 13, 2026

Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder

November 9, 2026

Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs

October 20, 2026

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

September 24, 2026

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

September 22, 2026

Vistagen to Present at Psych Congress 2026

September 10, 2026

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

August 14, 2026

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

August 6, 2026

Vistagen Appoints Douglas J. Williamson to its Board of Directors

July 31, 2026

Vantage: Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)

July 27, 2026

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

June 30, 2026

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

June 15, 2026

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

June 9, 2026

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

May 27, 2026

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

May 18, 2026

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

May 12, 2026

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

May 8, 2026

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

April 21, 2026

Vistagen to Participate in Upcoming Investor Conferences

March 3, 2026

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

February 25, 2026

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

February 12, 2026

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

February 4, 2026

Calls in 2026

Decks in 2026